In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m 2 to the classical association of fludarabine, 30 mg/m 2 /day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM with the FLUIM regimen (group A), and 124 received BM (n = 22) or PBSC (n = 102) with another RIC regimen (group B). Donors were siblings (n = 123) or HLA-matched 10/10 unrelated (n = 52). Full donor-type chimerism at day 100 was more often recorded in group A (86%) than in group B (62%); P o0.001. There was no difference between the two groups in terms of OS and EFS, acute GVHD, relapse and non-relapse mortality incidence. cGVHD occurred more often in group B (41%) than in group A (23%); P = 0.021. In multivariate analysis, the two risk factors associated with the development of cGVHD were conditioning in group B (hazard ratio (HR) = 2.871, 95% confidence interval (CI) (1.372-6.006); P = 0.005) and CD34
INTRODUCTION
Reduced-intensity conditioning (RIC) has made allo-SCT a possible therapeutic option for patients with hematologic malignancies who are unable to tolerate myeloablative regimens because of old age, compromised organ function or intensive pretreatment. [1] [2] [3] [4] [5] Traditionally, the goal of the preparative regimen has been eradication of the malignancy as well as providing sufficient immunosuppression and creating marrow space to prevent graft rejection. This belief has been questioned to reduce the toxicity of the conditioning and generate more graft-versus-malignancies effects. Initial data have demonstrated the feasibility of engraftment using PBSC after conditioning with only low-dose (200 cGy) TBI and a combination of Cs-A and mycophenolate mofetil. 2, 6, 7 Then, fludarabine was successfully added for 3 days because 18% of the patients had experienced non-fatal graft rejection with TBI alone. 3 Since the late 1990s, several other non-myeloablative regimens have been developed, using PBSC as source of stem cells. 5 This choice is explained by the high level of CD34 + cells and T lymphocytes in PBSC grafts, which allows a better engraftment than BM grafts. [8] [9] [10] [11] [12] However, PBSC has also been shown to increase the risk of chronic GVHD (cGVHD) compared with BM. [13] [14] [15] [16] Such a complication affects patients' quality of life and is associated with a higher risk of infections and death. 17 In an attempt to reduce the incidence of cGVHD after RIC, we decided to use BM infusion and elaborated an intermediate intensity conditioning, FLUIM. Because of its potent immunosuppressive effects, ability to ablate recipient's BM, broad antitumor activity and minimal extramedullary toxicity, 18 melphalan appeared to be a reliable option to improve RIC. As a single agent, melphalan is known to be adequately immunosuppressive and myeloablative allowing BM engraftment in allo-SCT. 19 Its synergy with fludarabine has also been shown through inhibition of DNA damage repair. 20 Thus, we decided to add melphalan at an intermediate dose (100 mg/m 2 ) to the fludarabine-TBI conditioning regimen and conducted a retrospective analysis to compare the outcomes of patients who underwent allo-SCT with RIC in our institution.
PATIENTS AND METHODS
The study was approved by the independent protection committee of the North-West of France and conducted according to the declaration of Helsinki.
Patient selection
Transplantation modalities were made as homogenous as possible using the following inclusion criteria: patients older than 18 years who referred in the University Hospital of Lille for a first allo-SCT between 2000 and 2012. The source of stem cells was BM or PBSC from either a sibling or an unrelated donor that was HLA-A, -B, -Cw, -DR and -DQ identical at the allelic level. Exclusion criteria were myeloablative conditioning regimen, umbilical cord blood graft and unrelated HLA-mismatched donor (9/10). Data were collected from clinical files, laboratory and radiologic results. Using different methods of verification (matching of several sources of data, on-site verification and computerized search for discrepancy errors), data were cross-checked meticulously. 
Conditioning regimens and GVHD prophylaxis

Supportive care
Patients and donor management has been conducted according to the guidelines of the French Society of Bone Marrow Transplantations and Cell Therapies (SFGM-TC). [21] [22] [23] [24] [25] [26] [27] [28] After conditioning, patients were treated in high-efficiency particulate air-filtered facilities. Anti-infective prophylaxis consisted of fluconazole and valacyclovir. Sulfamide-based treatment was given for Pneumocystis jirovecii and toxoplasmosis prophylaxis. Broadspectrum antibiotics, antifungal, antiparasitic and antiviral drugs were added as clinically indicated, according to SFGM-TC guidelines. 24, 28 Hemoglobin level and platelet count were maintained above 8 g/dL and 10 × 10 9 /L, respectively.
Patient and donor characteristics
Patient and donor initial characteristics at diagnosis and at transplant are given in Table 1 . Initially, we added melphalan to the Seattle RIC regimen for patients with multiple myeloma. Then, the FLUIM regimen was extended to other diseases. Therefore, the two groups are unbalanced in terms of diagnosis distribution with significantly more multiple myeloma in group A than in group B (P = 0.045). Median recipient age was higher in group A (59.4 years) compared with group B (55 years, P = 0.022). No difference was observed between the two groups in terms of sex ratio, disease status, median donor age, sex mismatch and donor HLA match.
Definition of end points
The primary end point was the incidence of cGVHD. The secondary end points included 2-years OS, engraftment, chimerism at day +100, acute GVHD, relapse, EFS and non-relapse mortality (NRM). Acute and cGVHD were diagnosed and graded according to standard criteria. 29, 30 Acute GVHD was censured at day +120 to include late acute GVHD. Engraftment was defined as absolute neutrophil count above 0.5 × 10 9 /L and platelet count above 50 × 10 9 /L for three consecutive days (the first of which was considered the day of engraftment). Chimerism was assessed on peripheral T lymphocyte DNA by quantitative PCR. EFS was defined as survival with no evidence of relapse and NRM as death with no evidence of relapse.
Statistical analysis
Continuous variables were expressed as median (range) or mean (s.d.) and were compared using the Mann-Whitney U test or T test, as appropriate. The qualitative variables were expressed as frequencies and percentages and were compared using the chi-square test or Fisher's exact test where appropriate. All the variables depicted in Table 1 , which comprise conditioning regimens and stem cell source, were assessed for inclusion in the following analyses. OS and EFS were calculated by Kaplan-Meier method, and the differences between groups were compared using the log-rank test. To identify predictive variables of OS or EFS, continuous variables were analyzed by a Cox proportional hazards model and qualitative variables using the log-rank test. For OS, all variables with P-value less than 0.2 in the previous analysis were introduced in a backward step by step Cox proportional hazards model to identify independent factors.
To identify predictive variables of acute and cGVHD or relapse, death of patient was considered as a competing risk of the event. For NRM, the competing event was relapse. Therefore, continuous variables were analyzed by a proportional hazards model of a competing risk according to Fine and Gray model, 31 and qualitative variables were analyzed by estimating cumulative incidence from competing risks and by testing equality across groups. For cGVHD, all variables with P-value less than 0.2 in the previous analysis were introduced in a backward step by step Cox proportional hazards model of a competing risk to identify independent factors.
All analyses were performed with SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA) and R Development Core Team (2011). A P-value o0.05 was considered statistically significant. The Cox proportional hazards model was used to identify continuous variables.
RESULTS
At the analysis date (1 April 2012), the median follow-up was 69 months (range, 12-308). The source of stem cells was BM in 51 patients (100%) in group A and 22 patients (17.7%) in group B, and PBSC in 102 patients (82.3%) in group B. Seattle conditioning was administrated to 93 patients (75.0%) and Slavin conditioning to 31 patients (25.0%) in group B.
As expected, the numbers of nucleated cells and CD34 + cells were significantly higher in PBSC grafts than in BM (45.75 versus 22.02 × 10 8 /kg, P o 0.001 and 5.23 versus 3.17 × 10 6 /kg; P o 0.001, respectively). No significant difference was observed between groups A and B in terms of neutrophil engraftment, with a median time of 20 and 18 days, respectively (P = 0.446). Platelet recovery was significantly delayed in group A compared with group B (median time of 25 days versus 16 days; P = 0.013) and the median number of platelet transfusions was higher in group A (5, range 0-22) than in group B (1, range 0-14); P = 0.001. However, the median number of unit of packed RBCs transfused was not different between the two groups (in group A: 2, range 0-14; in group B: 0, range 0-15; P = 0.189). Finally, chimerism analyses at day +100 showed a more frequent 100% donor profile in group A than in group B (85.7% of patients versus 61.6%; P o 0.001) (Figure 1 ). Abbreviations: ATG = antithymocyte globulin; Flu = fludarabine; Mel = melphalan; No = number; pts = patients. a Sex mismatch is defined as male recipient who received graft from female donor.
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Chronic GVHD As shown in Table 2 and Figure 2 , the 2-year cumulative incidence of cGVHD was significantly higher in group B than in group A (40.9% of patients versus 22.8%; P = 0.021). This difference was also observed in terms of extensive cGVHD with a 2-year incidence of 14.4% in group A versus 31.9% in group B (P = 0.019). BM grafts were associated with less cGVHD than PBSC grafts (P = 0.010).
In a multivariate analysis, the two risk factors associated with the development of cGVHD were conditioning regimen used in group B (hazard ratio (HR) = 2.871, 95% confidence interval (CI) (1.372-6.006); P = 0.005) and CD34 + cells count (HR = 1.009, 95% CI (1.006-1.011); P = 0.01) ( Table 3 ). The use of antithymocyte globulin had no significant impact on cGVHD.
Acute GVHD The 120-day cumulative incidences of acute grade II-IV GVHD (41.2% in group A and 39.5% in group B; P = 0.824) (Table 2, Figure 3 ) and severe acute grade III-IV GVHD (29.4% in group A and 21.8% in group B; P = 0.240) were not different between the two groups. In univariate analysis, the 120-day cumulative incidence of acute grade II-IV GVHD was significantly increased in patients in relapse/progression or partial response compared to patients in complete response at transplant (54.3, 44.8 and 24.2%, respectively; P = 0.008).
OS, EFS, relapse and non-relapse mortality
The 2-year OS was 58.7% in group A and 47.9% in group B (P = 0.338) ( Table 2 and Figure 4) . In multivariate analysis, only chimerism at day +100 was a protective factor of OS (HR = 0.990, 95% CI (0.984-0.996); P = 0.003) ( Table 3 ). As shown in Table 2 , the 2-year cumulative incidence of relapse rate and the 2-year EFS were not significantly different between group A and B (P = 0.679 and P = 0.705, respectively). The 2-year cumulative incidence of NRM was 24.2% in group A and 25.6% in group B (P = 0.993). There was no significant difference regarding the incidence of infection between the two groups. In group A, 24 patients (47%) experienced an infectious complication compared to 45 patients (36%) in group B, P = 0.185. However, patients with infectious complications had a higher incidence of NRM than the other patients (32.2% versus 18.1%, respectively; P = 0.002).
DISCUSSION
Findings from this study suggest that BM infusion following FLUIM intermediate intensity conditioning can lead to a decreased incidence of cGVHD compared with other RIC regimens. FLUIM was associated with a more frequent 100% donor profile chimerism 100 days after allo-SCT. Finally, 2-year EFS, OS, incidence of relapse and NRM were not compromised.
To the best of our knowledge, this is the first study reporting a protective effect of BM graft on cGVHD after a non-myeloablative conditioning of allo-SCT. Several studies have previously compared BM with PBSC grafts in allo-SCT, [13] [14] [15] [16] [32] [33] [34] [35] but RIC regimens were used only in one of them. 36 Because the outcome of allo-SCT depends on the degree of donor-recipient HLA matching, 37 we included only patients who received a graft from HLA-identical siblings or 10/10 matched unrelated donors. We demonstrate that BM infusion with FLUIM conditioning is safe and allows neutrophil engraftment similar to that with RIC using PBSC grafts. This could explain why patients who received FLUIM conditioning did not have more infectious complications than the others. As expected, [13] [14] [15] [16] [32] [33] [34] [35] the platelet recovery was slightly delayed after FLUIM regimen compared with the other regimens, but no major clinical issue was reported. The 2-year cumulative incidence of NRM was not different between the two groups. 
P=0.021
Group A Group B Figure 2 . Cumulative incidence of chronic GVHD (log-rank P-value).
Reduced intensity conditioning with bone marrow graftAlthough this study is retrospective, the two groups are well balanced in terms of sex ratio, pre-transplant disease status, sex mismatch and donor type. In the beginning, we only added melphalan to the conditioning for patients with multiple myeloma. This alkylating agent not only has an impact on the disease, but it can also improve the myeloablative and the immunosuppressive activity of the Seattle RIC regimen. [18] [19] [20] This may explain why the FLUIM regimen is associated with a more frequent 100% donor profile chimerism than the other regimens. Given the early promising results of FLUIM regimen, it was then transposed to other patients likely to benefit from BM transplantation.
In line with previous reports, [13] [14] [15] [16] 38 we found that PBSC graft had a detrimental impact on cGVHD development. Although 25% of the patients in group B received antithymocyte globulin, which is usually known to prevent GVHD onset, [39] [40] [41] patients in group A experienced cGVHD less often than in group B. However, one may question the reasons why such a beneficial effect of BM graft and FLUIM regimen in reducing cGVHD did not have an effect on survival. One should bear in mind that patients in group A were older than the other patients (P = 0.022). Because recipient's age is known to adversely influence survival, 42, 43 one could have expected an increased mortality in group A. Yet, the OS and the NRM were not different between the two groups. Therefore, the lower incidence of cGVHD might have played a role in the reduction of the expected mortality in the FLUIM group. Nevertheless, measuring the outcome of allo-SCT therapy remains difficult because the net outcome is affected by several complex variables that all might have a role in determining the final outcome. Either way, better GVHD prevention, even if it does not significantly improve survival, may still be a desirable approach, especially given the overall burden of cGVHD for patients. Of note, the incidence of acute GVHD was not increased in group A compared with group B, despite two potential risk factors: the older age of the patients 44 and the gastro-intestinal toxicity of melphalan. 45 In conclusion, the intermediate intensity conditioning FLUIM regimen was associated with a more frequent 100% donor profile chimerism at day +100 and a reduced incidence of cGVHD without compromising relapse and survival. FLUIM conditioning followed by BM infusion is feasible and shows promising results in comparison with other RIC regimens using PBSC. Abbreviations: CI = confidence interval; HR = hazard ratio; vs = versus; day +100 = 100 days after transplantation. NOTE. All the patients and transplant characteristics, conditioning regimens comprised, were assessed for inclusion in the multivariate analyses. All variables having a significance level of Po0.20 in the bivariate analyses were introduced in a multivariate model. Reduced intensity conditioning with bone marrow graft E Gomez et al
